

UPDATE ON HUMAN PROTEOME ORGANIZATION EXTERNAL DEVELOPMENT INITIATIVE

The mission of the Human Proteome Organization has established a HUPO External Development Initiative (HEDI) committee to foster integration between the HUPO membership and international thought leaders who are responsible for developing a strategy for funding proteomic-centric projects in their respective countries. The specific goals of the HEDI includes:

- Identifying emerging scientific opportunities, rising public health challenges, or scientific knowledge gaps that merit further research by international funding agencies, non-profit governmental organizations, and foundations, hereafter called Funders.
- Understanding scientific priorities and strategic planning of Funders globally in developing and applying resources (databases, analytic tools, and methodologies) and producing specifications for new resources in support of proteomic research.
- Assisting the Funders to address areas of emerging scientific opportunities and public health challenges effectively
- Providing technical assistance to Funders in the development of proteomic-based initiatives.

To meet these goals, HEDI is convening a session on **Proteomics in the Eyes of Stakeholders: Research Market, Investment Strategies and Growth Outlook at the HUPO International Meeting in Cancun, 2022**

Date and Time: Monday, December 5, 2022, 14:30 to 15:30

Session Chair: Sudhir Srivastava, svrivasts@mail.nih.gov

There are three important factors that bring the discovery of science into the society: Innovation, Ingenuity, and Investments. These are all intertwined and inseparable - investment supports innovations and innovations drive investments. Innovations helps develop more effective detection and treatments for diseases. But that research – whether it's funded through the Government funds or private investments, including venture capitals, – will only truly benefit people and patients. In addition to the funds and grants provided by the Government in each country, venture capitals play an important role in supporting ideas, discovery, and realization of technologies into public health. However, private sectors consider a number of factors before investing in health care. The two important factors are the size of the market and products with a competitive edge. For example, genomics in precision medicine has attracted private investments from a variety of sectors because of its potential application in disease prevention, early detection, and treatments. However, proteomics has lagged behind and has not been able to generate the same level of enthusiasm from government, investors, and private donors. The proposed symposium will provide insight into the nuances of investments in proteomics by public, private and charity institutions.

The proposed symposium (90-min) will invite a leading cadre of industrial leaders who are astute in proteomic technologies and known for building infrastructure and technologies:

Title: Proteomics in the Eyes of Stakeholders: Venture Capitals and Research Investment Strategies

Symposium Chair: Sudhir Srivastava

Panelists:

1. Puneet Souda – Senior Analyst, SVB Securities Puneet.couda@svbsecurities.com
2. Will Geist, President, Protein Sciences Segment, BioTechne Will.Geist@bio-techne.com
3. Carl Raimond, Chief Commercial Officer, Olink Proteomics carl.raimond@olink.com
4. Dr. Gary Kruppa, VP of Proteomics at Bruker, Gary.Kruppa@bruker.com
5. Dr. John Baker, Senior VP, Product Portfolio and Innovation John.Baker@abcam.com